scholarly journals Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer

2008 ◽  
Vol 51 (24) ◽  
pp. 7933-7943 ◽  
Author(s):  
Ying Chen ◽  
Catherine A. Foss ◽  
Youngjoo Byun ◽  
Sridhar Nimmagadda ◽  
Mrudula Pullambhatla ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Imaging Agents ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Biomarkers in Prostate-Specific Membrane Antigen Theranostics

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1108
Author(s):  
Panagiotis J. Vlachostergios ◽  
Ioannis Zachos ◽  
Vassilios Tzortzis
Keyword(s):  
Prostate Cancer ◽  
Imaging Agents ◽  
Surrogate Markers ◽  
Prostate Specific Membrane Antigen ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Specific Membrane ◽  
Major Target

Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of 177Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Progression ◽  
Specific Membrane ◽  
Psma Expression

scholarly journals 225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

2021 ◽  
Vol 10 (5) ◽  
pp. 205846012110225
Author(s):  
Omer Aras ◽  
Stefan Harmsen ◽  
Richard Ting ◽  
Haluk B Sayman
Keyword(s):  
Prostate Cancer ◽  
Standard Of Care ◽  
Complete Response ◽  
Prostate Specific Membrane Antigen ◽  
Limited Data ◽  
Castrate Resistant Prostate Cancer ◽  
Targeting Peptide ◽  
Castrate Resistant ◽  
Specific Membrane

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.

Lectin bioreceptor approach in capacitive biosensor for prostate-specific membrane antigen detection in diagnosing prostate cancer

2021 ◽  
Vol 120 ◽  
pp. 9-16
Author(s):  
Indra Gandi Subramani ◽  
R.M. Ayub ◽  
Subash C.B. Gopinath ◽  
Veeradasan Perumal ◽  
M.F.M. Fathil ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Antigen Detection ◽  
Prostate Specific Membrane Antigen ◽  
Capacitive Biosensor ◽  
Specific Membrane
Sign in / Sign up

Export Citation Format

Share Document